Articles tagged with Cancer Patients
Researchers at the University of Helsinki and Aalto University have developed a gel-grown mini-breast cancer model that can effectively treat hormone-dependent breast cancers. The discovery opens new avenues for hormonal therapies, individual drug responses, and drug resistance mechanisms.
A new AI model has been developed to classify colorectal polyps, demonstrating accuracy and sensitivity at a level comparable to practicing pathologists. The model was tested in a clinical trial involving 15 pathologists, showing significant improvements in accuracy compared to traditional methods.
A study of 16,000 patients with new cancer diagnoses found that those from higher socioeconomic backgrounds were more likely to use telemedicine in the months following their diagnosis. Higher socioeconomic groups also showed increased utilization of telemedicine services within 30 days of diagnosis during the COVID-19 pandemic.
Researchers have developed an assay that uses specific immune-biomarkers to monitor patient survival chances and effectiveness of ovarian cancer treatments. The 'sFIS' assay will enable targeted therapy for each patient, improving treatment outcomes.
Researchers developed a novel model to identify specific genes and genetic alterations in multiple myeloma, stratifying the cancer's severity via DNA and RNA sequencing. This model revealed diverse subtypes and high-risk patients beyond current classifications.
A functional precision medicine study demonstrates that treatment selection based on results from drug sensitivity testing can be clinically useful in patients with aggressive hematological cancer. The approach combines deep molecular profiling with comprehensive drug sensitivity testing to advance the therapy decision-making system.
A survey of parents and caregivers of children with cancer revealed that nearly a third expressed hesitation to vaccinate against COVID-19. Factors associated with willingness or hesitancy included confidence in science, medicine, and vaccination, as well as concerns about infection risks and vaccine safety.
A Mount Sinai study reveals that young adult cancer patients exhibit distinct genetic hallmarks and immune system responses compared to their older counterparts. These findings suggest personalized treatment approaches for young adults with various types of cancers.
A new study by Montefiore Einstein Cancer Center investigators found that a COVID-19 booster shot helps most cancer patients with no immune response after two-dose vaccination, significantly increasing antibody levels. The study also shows that all cancer patients benefit from vaccination, particularly those with blood cancer.
A study found that lung cancer screening rates increased significantly among high-risk males who gained access to Medicare, with a 16% jump in screenings reported. The rise is attributed to the reduced out-of-pocket costs and greater access to care for these individuals, many of whom were previously uninsured.
A researcher at MUSC's Hollings Cancer Center is developing 'living drugs' by precision-engineering CAR Tregs to treat autoimmune diseases. The CAR Tregs can delay or reduce damaging inflammation, offering a potential solution for conditions like Type 1 diabetes.
Women with breast cancer are at a higher risk of developing atrial fibrillation and dying from heart-related issues within the first year. The condition was more common in women who did not receive surgery or radiation as their initial treatment.
This study found high expression of Myosin 1g in pediatric acute lymphoblastic leukemia, suggesting its potential role in disease pathogenesis, particularly in high-risk patients. The research also showed that Myo1g may serve as a biomarker for identifying patients with an increased risk of relapse.
A large group of patients with diverse cancer types received two doses of SARS-CoV-2 vaccines or one dose of the Johnson and Johnson vaccine, showing modestly impaired immune responses. Booster vaccine doses enhanced immunity in most patients.
Researchers have developed a simple, postal urine test that can detect signs of urothelial cancer in Lynch Syndrome (LS) patients, who are at high risk of developing tumors. The test uses cell-free DNA shed into the urine to identify DNA from tumor cells with characteristic microsatellite instability.
Researchers developed a mathematical model that can predict the effectiveness of immunotherapy treatment for individual patients based on standard clinical measures. The model showed high sensitivity in predicting treatment response within two months, with minimal false-negative results.
A Johns Hopkins-led study found that leptin cancels out the effects of Tamoxifen, making it ineffective for obese patients with breast cancer. Researchers suggest that interventions targeting leptin or Med1 may improve Tamoxifen's success in this group.
Researchers developed a blood test that can detect prostate cancer patients who are resistant to chemotherapy drug docetaxel, enabling early detection and personalized treatment. The test analyzes circulating tumor cells in the bloodstream, revealing patterns that predict disease progression and survival.
A phase 2 clinical trial shows durvalumab immunotherapy combined with standard chemotherapy significantly improved overall survival for patients with previously untreated malignant pleural mesothlioma. The study's findings provide insights into patient selection methods for this novel chemo-immunotherapy regimen.
A study found that patients from ethnic minority groups had lower mortality rates compared to white British people. Patients from Indian, Pakistani, and other ethnic backgrounds were 16-30% less likely to die within one year of diagnosis.
Researchers at Johns Hopkins Kimmel Cancer Center found a new treatment option for inoperable pleural mesothelioma using immunotherapy agent durvalumab combined with platinum-based chemotherapy. Patients with epithelioid tumors experienced higher survival rates, including some who remained tumor-free after completing the trial.
A pilot study reveals that whole genome sequencing can refine diagnoses and provide new treatment options for children with cancer. The study found genetic variants that could change prognosis or suggest hereditary causes of the cancers, as well as treatments that may be effective but were not previously considered.
According to experts, half of patients with two common subtypes of advanced breast cancer may live for five years or longer. The new guidelines also aim to improve treatment options for triple-negative breast cancer patients.
A study found that arginine treatment improved outcomes in cancer patients with brain metastases, showing a complete or partial response in nearly 78% of patients. The amino acid may be useful as an anticancer therapy when combined with radiotherapy or other treatments.
A study published in Nature Communications found that neuroendocrine tumors in the small intestine often originate from different cells with unique genetic mutations. This breakthrough challenges conventional wisdom on cancer development and highlights the importance of removing all detected tumors to prevent late relapses.
COVID-19 vaccinations have been shown to be safe for advanced breast cancer patients, with no notable differences between vaccine brands. The second dose is crucial to induce an immune response, which has been found in 80% of patients with solid tumours.
Researchers have identified genetic mutations in genes CBP and p300 that drive radiation resistance in head and neck tumors. Inhibiting these proteins with certain drugs makes tumor cells more susceptible to radiotherapy.
Researchers at Children's Hospital of Philadelphia have developed a novel therapy that targets proteins essential for tumor growth and survival. Using a multi-omics approach, they identified peptides unique to neuroblastoma tumors, which are then targeted by peptide-centric chimeric antigen receptors (PC-CARs).
A recent survey of advanced breast cancer patients in the UK reveals that only 14% have been recruited to a trial, highlighting a need for improved access. Patients often face barriers, including clinician reluctance to discuss trials and a lack of patient-friendly databases.
A Tulane University study successfully leverages artificial intelligence to identify and diagnose colorectal cancer with a performance comparable to, if not better than, highly experienced pathologists. The AI-powered program achieves an average accuracy of .98 in accurately identifying colorectal cancer from tissue scans.
A new pilot study reveals a prostate cancer urine test can identify men with intermediate-risk disease, allowing them to opt for active surveillance instead of immediate treatment. The test assesses the amount of aggressive cancer in the prostate without needing a biopsy.
A major global study found that the risk of breast cancer spreading to other parts of the body ranges from 6% to 22%. Younger women and those diagnosed with larger tumours face a higher risk. The study also sheds light on how many people develop advanced breast cancer, a gap in knowledge until now.
Researchers from MUSC Hollings Cancer Center, UCLA Jonsson Comprehensive Cancer Center, and Winship Cancer Institute discovered that pre-surgical anti-PD-1 immunotherapy is safe and effective for OCSCC patients. The studies identified potential molecular biomarkers in blood and tumors to predict treatment response.
Researchers found that certain T cells stop working before entering the tumor due to changes in gene expression, making ICB therapies less effective. Combining ICB with other forms of immunotherapy targeting different aspects of T cell function may improve response rates for non-small cell lung cancer patients.
A multi-center study demonstrated improved overall survival and quality of life for inoperable pancreatic cancer patients treated with MRIdian SMART, with a median survival of 26 months. The treatment showed low rates of major adverse events and was more effective than standard radiation therapy.
Researchers found immune cell patterns within tumours that can predict if patients with kidney cancer will respond to immunotherapy. The study identified a specific 'clonal' T cell receptor pattern linked to a greater chance of positive immunotherapy response.
A new study by Dana-Farber Cancer Institute found that younger patients with metastatic colorectal cancer have a similar overall survival time as older patients, defying expectations. The study included data from the CALGB/SWOG 80405 clinical trial and compared survival times in 514 younger patients under 50 with 1,812 older patients.
Researchers at Duke University and UC Irvine identify Kenpaullone, a cancer drug, as an effective analgesic for chronic and challenging-to-treat pain. The compound enhances Kcc2 gene expression, which resets maladaptive genetic switches in neurons, leading to pain signal silencing.
A team of researchers has developed an ensemble-based machine learning model that can predict how cancer patients will respond to certain drugs with high accuracy. The model was trained on data from 499 independent cell lines and validated against a clinical dataset containing seven chemotherapeutic drugs.
A new report reveals that cancer patients in the US bear a significant financial burden, with total out-of-pocket costs reaching over $21 billion in 2019. The majority of these costs are associated with breast and prostate cancers, which are among the most prevalent types in the country.
A Singapore clinical trial has introduced a new way to treat advanced hepatocellular carcinoma by combining nivolumab, an immunotherapy drug, with yttrium-90 resin microspheres radioembolisation. The study shows promising results in treating intermediate and advanced HCC, with an overall response rate of 30.6%.
A new study finds that high-dose radiation therapy can lengthen progression-free survival for people with advanced lung cancer when systemic therapy has not fully halted tumor growth or spread. Stereotactic body radiation therapy (SBRT) shows promise in treating oligoprogressive, metastatic lung and breast cancer.
A recent clinical trial found that a shortened course of radiation therapy after prostate removal surgery does not increase long-term side effects or lower quality of life compared to conventional treatment. Patients who underwent hypofractionated, post-operative radiation therapy experienced comparable genitourinary and gastrointestin...
A new analysis of US national data finds that external-beam radiation therapy is a proven treatment option for patients with unresectable liver cancer but is rarely prescribed, with only 3.6% of patients receiving it. The study suggests that institutional and regional practice patterns play a key role in driving treatment decisions.
Two studies investigate the factors associated with cancer centers offering telehealth services, revealing regional disparities and socio-economic influences. Researchers aim to increase access to care for patients who may be underserved or lack technology to participate in remote visits.
ImCheck's ICT01 selectively activates Vγ9Vδ2 T cells through all three isoforms of BTN3A, overcoming prior limitations. The therapy demonstrates anti-tumor activity in solid and hematologic cancer models.
The MUSC Hollings Cancer Center researchers are exploring the role of macroenvironment in pancreatic cancer-induced cachexia to address this debilitating condition. The team aims to provide new biological insight, which will be coordinated by four cores within the program project grant.
A study published in JNCCN found that 45% of people with cancer prefer telemedicine over in-person visits, while general patient satisfaction scores are equally high. The research also revealed that patients preferred video conferencing over audio-only appointments and that telemedicine can reduce treatment-related costs.
The new ESMO Clinical Practice Guideline provides comprehensive guidance on diagnosing, staging, and treating patients with metastatic breast cancer. The guideline incorporates recent clinical trial data to inform treatment choices, taking into account tumour biology and emerging targeted therapies.
A new study found that translocator protein 18 kDa (TSPO) correlates with worse survival outcomes in male glioblastoma patients compared to females. The variation in the protein's structure is associated with shorter overall and progression-free survival times, suggesting its potential as a prognostic biomarker.
Patients with multiple myeloma often mount a poor antibody response to COVID-19 vaccines and have a weak T cell response, underscoring the need for booster vaccination and safety precautions. Researchers found that these patients are at high risk of severe COVID-19 infection.
Researchers from UPV/EHU and Biocruces pathologists use game theory to study tumor cell interactions, finding that higher cell diversity may be beneficial for patients. This approach reveals the importance of collective stability in tumor cells' pursuit of better environments.
Researchers at the University of Copenhagen have discovered that the BRCA2 gene requires a specific enzyme, PP2A-B56, to repair DNA damage. This finding may pave the way for more targeted treatment of cancer patients with certain mutations.
Scientists developed a fluorescent spray that specifically targets and illuminates cancerous tissue, enabling precise tumor detection and removal during surgery. The innovative approach offers a solution to the challenge of distinguishing between healthy tissue and cancerous cells.
A survey of breast cancer patients found that nearly half use cannabis to alleviate pain, fatigue, and other symptoms while undergoing treatment. Physicians are often unaware of patients' cannabis use, highlighting the need for informed conversations about its potential benefits and risks.
A peptide-drug conjugate called CBX-12 has been shown to enhance the efficacy of immune checkpoint inhibitors in preclinical cancer models by targeting the acidic environment of cancer cells. The treatment exhibited significantly delayed tumor growth, improved survival, and complete tumor regressions compared to immunotherapy alone.
A recent study found that non-Hispanic Black patients who received immunotherapy for advanced-stage non-small cell lung cancer had a lower risk of death compared to non-Hispanic white patients. The researchers controlled for access-related issues and found disparities persisted in certain populations.
A new study reveals that COVID-19 lockdowns led to significant delays in cancer surgery, resulting in potentially more cancer deaths. Patients in lower income countries and those with advanced disease were most affected, with one in seven missing their scheduled operation.
MUSC researcher Haizhen Wang receives R37 grant to investigate CDK6's role in T-cell acute lymphoblastic leukemia, a aggressive cancer. The research aims to understand how the immune system can be used to reduce leukemia progression.
A new study from the University of Eastern Finland and Kuopio University Hospital found that liquid biopsy can accurately identify patients with poor breast cancer prognosis. High integrity of circulating DNA is associated with a poor prognosis, enabling earlier and more accurate detection of breast cancer. The study's findings have si...